Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.61 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.47 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.46 |
| ▸ | HRH1 | P35367 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2885713 | 0.89 | HRH3 (0.70) | HRH3 | |
| SCHEMBL1813613 | 0.85 | HRH3 (0.48) | HRH3 | |
| SCHEMBL2878928 | 0.82 | HRH3 (0.56) | HRH3 | |
| SCHEMBL2886071 | 0.77 | HRH3 (0.71) | HRH3 | |
| SCHEMBL2881658 | 0.76 | HRH3 (1.00) | HRH3CHRM1HRH1KCNH2 | |
| SCHEMBL2885885 | 0.76 | HRH3 (1.00) | HRH3CHRM1HRH1KCNH2 | |
| SCHEMBL2878779 | 0.76 | HRH3 (1.00) | HRH3CHRM1HRH1KCNH2 | |
| SCHEMBL6821149 | 0.75 | GRIK1 (0.75) | GRIK1GRIK2 | |
| SCHEMBL1811112 | 0.74 | L3MBTL3 (0.47) | HRH3 | |
| SCHEMBL1814566 | 0.73 | HRH3 (0.55) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7820825-B2 | N-substituted-azacyclylamines as histamine-3 antagonists | WYETH LLC (US) | 2010-10-26 | — | — | US | claimed |
| US-20070219240-A1 | N-substituted-azacyclylamines as histamine-3 antagonists | WYETH (US) | 2007-09-20 | — | — | US | claimed |
| US-8796247-B2 | Indole derivative, and pharmacologically acceptable salt thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2014-08-05 | — | — | US | disclosed |
| US-8796247-B2 | Indole derivative, and pharmacologically acceptable salt thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2014-08-05 | — | — | US | disclosed |
| US-20140018335-A1 | INDOLE DERIVATIVE, AND PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2014-01-16 | — | — | US | disclosed |
| US-20140018335-A1 | INDOLE DERIVATIVE, AND PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2014-01-16 | — | — | US | disclosed |
| WO-2012102254-A1 | INDOLE DERIVATIVE, AND PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF | キッセイ薬品工業株式会社 (JP) | 2012-08-02 | — | — | WO | disclosed |
| US-7820825-B2 | N-substituted-azacyclylamines as histamine-3 antagonists | WYETH LLC (US) | 2010-10-26 | — | — | US | disclosed |
| EP-1994022-A2 | N-SUBSTITUTED-AZACYCLYLAMINES AS HISTAMINE-3 ANTAGONISTS | Wyeth a Corporation of the State of Delaware (US) | 2008-11-26 | — | — | EP | disclosed |
| WO-2007108936-A2 | N-SUBSTITUTED-AZACYCLYLAMINES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2007-09-27 | — | — | WO | disclosed |
| US-20070219240-A1 | N-substituted-azacyclylamines as histamine-3 antagonists | WYETH (US) | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140018335-A1 | INDOLE DERIVATIVE, AND PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF | PTGER1, CYSLTR1, LTB4R | HRH3 250/4885GRIK1 256/4885GRIK2 846/4885 |
| US-20070219240-A1 | N-substituted-azacyclylamines as histamine-3 antagonists | HNMT, HRH4, HRH3 | HRH3 3/4885GRIK1 134/4885GRIK2 117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.